Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

CJC-1295 With DACUnderstand the science

How long did growth hormone and IGF-1 change in early human trials?

2 numbered sourcesSource years 2005, 2024

Peptides are short chains built from amino acids and joined by peptide bonds. Some act like the natural signals that tell the pituitary gland to release a hormone. CJC-1295 With DAC is an investigational form of a growth hormone–releasing hormone (GHRH) analogue. Its attached drug affinity complex (DAC) allows it to bind to blood proteins. Early studies asked how long the circulating peptide and its effects could be measured in healthy adults. [1, 2]

No recent primary human trial measuring the duration of these responses was identified. The older direct evidence comes from two randomized, double-blind, placebo-controlled studies reported together by Teichman and colleagues. The team measured the study compound as well as growth hormone (GH) and insulin-like growth factor 1 (IGF-1), a downstream signal that responds to GH. The estimated half-life of the compound ranged from 5.8 to 8.1 days across the estimates reported. Mean GH concentrations remained elevated for at least six days after one exposure, and mean IGF-1 concentrations rose for about nine to eleven days. [1]

A half-life describes how long it takes the measured concentration to fall by half in the relevant part of its decline. It is different from the time a downstream hormone stays elevated. The researchers' separate measurements make it possible to see that difference. Their placebo comparisons help isolate the short-term endocrine effects within the study design. [1]

The endpoints were blood concentrations in healthy adults. They did not establish that a persistent increase would improve growth, physical function, or any other patient outcome. The published studies were brief and reported no serious adverse reactions, while the FDA's later assessment noted reactions including flushing, headache, and injection-site symptoms. Longer observation and studies in defined patient populations would be needed to describe the clinical effects and risks. [1, 2]

Sources

Original works cited in this article. Links open the external record in a new tab.

Shop CJC-1295 With DAC

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Also available as Markdown or JSON.